ADARx Pharmaceuticals (ADRX) Stock Price, News & Analysis

Company Overview

ADARx Pharmaceuticals is a clinical-stage biopharmaceutical company developing RNA-targeted medicines for serious diseases. Its research focuses on oligonucleotide therapeutics designed to alter the activity of specific RNA molecules and, in turn, address disease-related gene expression.

The company’s pipeline includes investigational candidates for conditions such as hereditary angioedema and complement-mediated diseases. These therapies remain in development and have not been established as approved treatments.

ADARx is based in San Diego, California, and was founded to develop medicines using its RNA-targeting technology. The company’s work spans drug discovery and clinical development; details about its programs and leadership may change as its research advances.

Key Stats

• Today's Range: $13.17 to $14.07
• 50-Day Range: N/A
• 52-Week Range: $12.50 to $23.21
• Volume: 509,928 shs
• Average Volume: 377,940 shs
• Market Capitalization: $1.42 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Moderate Buy

ADARx Pharmaceuticals Stock Analysis - MarketRank™

ADARx Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ADARx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

ADARx Pharmaceuticals has a consensus price target of $35.00, representing about 163.2% upside from its current price of $13.30.

Amount of Analyst Coverage

ADARx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ADARx Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.61) per share.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.69% of the float of ADARx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ADARx Pharmaceuticals has a short interest ratio ("days to cover") of 5.02.

Change versus previous month

Short interest in ADARx Pharmaceuticals has recently decreased by 5.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADARx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ADARx Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.89

News Sentiment

ADARx Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ADARx Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for ADRX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added ADARx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of ADARx Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $55,445,772.00 in company stock, which represents 3.9034% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, ADARx Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,445,772.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

ADARx Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ADRX
• CIK: 1802369
• Web: www.adarx.com
• Phone: (858) 283-9472
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ADARx Pharmaceuticals: $35.00
• High Price Target: $38.00
• Low Price Target: $32.00
• Potential Upside/Downside: +163.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 106,800,000
• Free Float: N/A
• Market Cap: $1.42 billion
• Optionable: N/A
• Beta: N/A